| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview |
Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Donald J. Tindall, Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905. E-mail: tindall.donald{at}mayo.edu.
The androgen receptor (AR) is a nuclear receptor transcription factor that mediates the cellular actions of androgens, the male sex steroids. Androgen-dependent tissues, such as the prostate, rely on androgen action for their development as well as their maintenance in adulthood. This requirement is exploited during systemic therapy of prostate cancer, which is initially an androgen-dependent disease. Indeed, androgen ablation, which prevents the production or blocks the action of androgens, inhibits prostate cancer growth. Invariably, the disease recurs with a phenotype resistant to further hormonal manipulations. However, this so-called androgen depletion-independent prostate cancer remains dependent on a functional AR for growth. Many studies have focused on the mechanistic and structural basis of AR activation with the important goal of understanding how the AR is activated at this stage of the disease. In this review, we summarize how these studies have revealed important functional domains in the AR protein and have provided initial clues to their role in prostate cancer development and progression. A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  J. Ribas, X. Ni, M. Haffner, E. A. Wentzel, A. H. Salmasi, W. H. Chowdhury, T. A. Kudrolli, S. Yegnasubramanian, J. Luo, R. Rodriguez, et al. miR-21: An Androgen Receptor-Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth Cancer Res., September 15, 2009; 69(18): 7165 - 7169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Baniwal, O. Khalid, D. Sir, G. Buchanan, G. A. Coetzee, and B. Frenkel Repression of Runx2 by Androgen Receptor (AR) in Osteoblasts and Prostate Cancer Cells: AR Binds Runx2 and Abrogates Its Recruitment to DNA Mol. Endocrinol., August 1, 2009; 23(8): 1203 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jin and J. D. Fondell A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression Nucleic Acids Res., August 1, 2009; 37(14): 4826 - 4838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Stan and S. V. Singh Transcriptional Repression and Inhibition of Nuclear Translocation of Androgen Receptor by Diallyl Trisulfide in Human Prostate Cancer Cells Clin. Cancer Res., August 1, 2009; 15(15): 4895 - 4903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Knudsen and H. I. Scher Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer Clin. Cancer Res., August 1, 2009; 15(15): 4792 - 4798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eisold, M. Asim, H. Eskelinen, T. Linke, and A. Baniahmad Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens J. Mol. Endocrinol., May 1, 2009; 42(5): 429 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Pignon, B. Koopmansch, G. Nolens, L. Delacroix, D. Waltregny, and R. Winkler Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines Cancer Res., April 1, 2009; 69(7): 2941 - 2949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Yang, Y-L Zhao, Z-Q Wu, Y-L Si, Y-G Meng, X-B Fu, Y-M Mu, and W-D Han The single-macro domain protein LRP16 is an essential cofactor of androgen receptor Endocr. Relat. Cancer, March 1, 2009; 16(1): 139 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hu, T. A. Dunn, S. Wei, S. Isharwal, R. W. Veltri, E. Humphreys, M. Han, A. W. Partin, R. L. Vessella, W. B. Isaacs, et al. Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer Cancer Res., January 1, 2009; 69(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, M. H. Muders, J. Li, F. Rinaldo, D. J. Tindall, and K. Datta Loss of NKX3.1 Favors Vascular Endothelial Growth Factor-C Expression in Prostate Cancer Cancer Res., November 1, 2008; 68(21): 8770 - 8778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Khan, M. Asim, F. Afaq, M. Abu Zaid, and H. Mukhtar A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude Mice Cancer Res., October 15, 2008; 68(20): 8555 - 8563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Dehm, L. J. Schmidt, H. V. Heemers, R. L. Vessella, and D. J. Tindall Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance Cancer Res., July 1, 2008; 68(13): 5469 - 5477. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
